Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Gianni

Showing results (1-10 of 151) with videos related to

Pageof 16
Sort By:
Lancet (London, England)|February 2, 2010
An interview with Luca GianniLuca Gianni
The Lancet. Oncology|May 29, 2018
Is there room for another HER2-targeting drug?Luca Gianni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Ixabepilone and the narrow path to developing new cytotoxic drugsLuca Gianni
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
The cost of life: should it matter to doctors?Luca Gianni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
The "other" signaling of trastuzumab: antibodies are immunocompetent drugsLuca Gianni
Breast Cancer Research and Treatment|April 24, 2009
Never use anthracyclines with trastuzumab: it is time to reconsider the tabooLuca Gianni
Oncology|November 8, 2002
The future of targeted therapy: combining novel agentsLuca Gianni
Nature Clinical Practice. Oncology|November 3, 2005
Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancerLajos Pusztai, Luca Gianni
Lancet (London, England)|December 13, 2016
HER2-positive breast cancerSibylle Loibl, Luca Gianni
Cell Research|May 10, 2014
Hallmarks of triple negative breast cancer emerging at last?Rosa Bernardi, Luca Gianni
Pageof 16

Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Lancet (London, England)|February 2, 2010
An interview with Luca GianniLuca Gianni
The Lancet. Oncology|May 29, 2018
Is there room for another HER2-targeting drug?Luca Gianni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2007
Ixabepilone and the narrow path to developing new cytotoxic drugsLuca Gianni
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2006
The cost of life: should it matter to doctors?Luca Gianni
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2008
The "other" signaling of trastuzumab: antibodies are immunocompetent drugsLuca Gianni
Breast Cancer Research and Treatment|April 24, 2009
Never use anthracyclines with trastuzumab: it is time to reconsider the tabooLuca Gianni
Oncology|November 8, 2002
The future of targeted therapy: combining novel agentsLuca Gianni
Nature Clinical Practice. Oncology|November 3, 2005
Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancerLajos Pusztai, Luca Gianni
Lancet (London, England)|December 13, 2016
HER2-positive breast cancerSibylle Loibl, Luca Gianni
Cell Research|May 10, 2014
Hallmarks of triple negative breast cancer emerging at last?Rosa Bernardi, Luca Gianni
Pageof 16